Pharmesis International Ltd
BFK
Company Profile
Business description
Pharmesis International Ltd is an investment holding company. The company manufactures pharmaceutical products in the form of tablets, granules, pills, and other forms. Its operating segments are Western drugs, which are chemically formulated drugs and are marketed under the Kinna brand; TCM-formulated drugs, which refer to Traditional Chinese Medicine and are marketed under the Longlife brand; and Distribution. The company derives revenue from the sale of medicines to domestic customers in China.
Contact
5 Kallang Sector
No. 03-02
Singapore349279
SGPT: +65 68460766
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
Stocks News & Analysis
stocks
Signs of a turnaround for undervalued ASX share
Market likes the payoff from early efforts at reining in costs.
stocks
Australia has the highest dividend yields in the world, so why the endless chase for even higher yields?
Ashley Owen explores why investors' insatiable thirst for higher yields leads to unnecessarily complicating their portfolio.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,825.10 | 20.90 | 0.24% |
| CAC 40 | 8,178.54 | 14.43 | 0.18% |
| DAX 40 | 22,513.42 | 98.60 | -0.44% |
| Dow JONES (US) | 44,546.08 | 165.35 | -0.37% |
| FTSE 100 | 8,732.46 | 32.26 | -0.37% |
| HKSE | 22,620.33 | 805.96 | 3.69% |
| NASDAQ | 20,026.77 | 81.13 | 0.41% |
| Nikkei 225 | 39,149.43 | 312.04 | -0.79% |
| NZX 50 Index | 12,989.18 | 83.20 | 0.64% |
| S&P 500 | 6,114.63 | 0.44 | -0.01% |
| S&P/ASX 200 | 8,555.80 | 15.80 | 0.19% |
| SSE Composite Index | 3,346.72 | 14.24 | 0.43% |